KyungDong Pharm home
Prescription Medicines

Dapamet SR Tab. 10/500mg

Product Category
Diabetes treatment
Active Ingredients
Dapagliflozin, metformin hydrochloride
Appearance
Pink, oval, biconvex film-coated tablets
Reimbursement Code
648104840
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredients:
Dapagliflozin Bis L-Proline (in-house specification) ----- 15.63mg (10mg as dapagliflozin)
Metformin hydrochloride (in-house specification) ----- 500.00mg
- Additives (animal-derived ingredients): Anhydrous lactose (cow, milk)
- Other additives: Calcium silicate, microcrystalline cellulose, magnesium stearate, Opadry II pink (85F94333), silicon dioxide, low-substituted hydroxypropyl cellulose, hypromellose

2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve glycemic control in adult patients with type 2 diabetes who are suitable for combined administration of dapagliflozin and metformin.
For the effect of dapagliflozin on cardiovascular events in patients with inadequately controlled type 2 diabetes and established cardiovascular disease or cardiovascular risk factors, see “Precautions for Use, 13. Information for Healthcare Professionals, 2) Clinical Study Information.”

3. Dosage and dosage
The dosage of this drug should be individualized based on the patient's current treatment, effectiveness and tolerability, without exceeding the maximum recommended dose of 10 mg of dapagliflozin and 2000 mg of sustained-release metformin.
This medication is generally administered once daily with dinner.
The maximum dose of this drug is 10 mg of dapagliflozin/2000 mg of extended-release metformin once a day, and is administered as 2 tablets of 5 mg/1000 mg.
If you have not previously received diabetes medication and are unable to sufficiently control blood sugar levels with monotherapy:
When used as initial therapy in those who have not previously received diabetes medication, the recommended starting dose of this drug is one tablet of 5 mg/500 mg or 10 mg/500 mg once daily.
Adjust the dose gradually to reduce the gastrointestinal side effects of metformin.
In patients being treated with metformin, the recommended dose of dapagliflozin is 10 mg once a day, and the dose of this drug should be provided at an appropriate dose that is therapeutically close to the dose of metformin being taken. When switching from metformin immediate-release to sustained-release formulations, glycemic control should be closely monitored and dosage adjustments should be made appropriately.
In patients switching from dapagliflozin and metformin combination therapy to this drug, the dose of this drug can be started at the existing dose of dapagliflozin and metformin. When switching from metformin immediate-release to sustained-release formulations, glycemic control should be closely monitored and dosage adjustments should be made appropriately.
If this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and effectiveness of this drug have not been specifically evaluated in patients switching to this drug from other hypoglycemic agents. Any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring because they may cause changes in glycemic control.
This medication should be swallowed whole and should never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the feces in the form of soft tablet-like hydrates.
renal impairment
No dose adjustment is necessary for patients with mild renal impairment.
For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more but less than 60 mL/min/1.73 m2 and no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500 mg once daily, and the maximum daily dose is 1000 mg.
It is not recommended to administer this drug to patients with eGFR less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73 m2, this drug should be discontinued immediately. Renal function should be assessed every 3 to 6 months.
elderly people
Metformin is excreted through the kidneys, and because renal function is prone to decline in the elderly, this drug should be used with caution as age increases (see Precautions for Use, Section 9. Administration to the Elderly).

4. Precautions for use
1. Warning
metformin hydrochloride
1) In very rare cases, severe lactic acidosis may occur. (Refer to 5. General precautions) Cases of death due to lactic acidosis have been reported.
2) When administered concurrently with other antidiabetic agents such as insulin or sulfonylurea, caution is required as severe hypoglycemia may occur in rare cases.

2. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to the main ingredients or excipients of this drug
2) Patients with moderate (stage 3b) and severe renal impairment defined as creatinine clearance less than 45 mL/min or estimated glomerular filtration rate less than 45 mL/min/1.73m2
3) Acute conditions that can affect renal function, such as dehydration, serious infections, cardiovascular collapse (shock), acute myocardial infarction, and sepsis.
4) Patients with acute or chronic metabolic acidosis, including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis [Type 1 diabetes and diabetic ketoacidosis are treated with insulin].
5) Diabetic precoma
6) Patients with congestive heart failure requiring drug treatment
7) Patients undergoing tests that involve intravenous administration of radioiodine contrast material (e.g., intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast media, etc.) (can cause acute renal failure, and are associated with lactic acidosis in patients receiving this drug. Therefore, in patients scheduled for such tests, this drug should be stopped at least 48 hours before administration, and renal function should be reevaluated after 48 hours and found to be normal. Treatment is resumed only after this.)
8) In patients with severe infections or severe traumatic systemic disorders, treatment with this drug should be temporarily stopped and treatment should be restarted when the patient's oral intake is restored and renal function is found to be normal.
9) In case of surgical procedures (excluding minor surgeries without restrictions on food and fluid intake), this drug should be temporarily discontinued 48 hours before surgery, and treatment should be restarted at least 48 hours after renal function is confirmed to be normal.
10) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
11) Impaired liver function (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), acute or chronic diseases that can cause tissue hypoxia such as respiratory failure, acute myocardial infarction, and shock, excessive alcohol intake, and patients with gastrointestinal disorders such as dehydration, diarrhea, and vomiting.
12) Pregnant women, women who may be pregnant, and lactating women
13) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

3. Administer with caution to the following patients:
1) Administration in patients with decreased body volume and renal dysfunction
Dapagliflozin may cause a decrease in intravascular blood volume, which may manifest as symptomatic hypotension or sudden and temporary changes in creatinine. In foreign post-marketing surveillance, acute kidney injury was reported in patients administered SGLT-2 inhibitors, including dapagliflozin, and some required hospitalization and dialysis. The risk of hypovolemia or hypotension may increase in patients with renal dysfunction (eGFR less than 60mL/min/1.73m2), the elderly, and those using loop diuretics.
For patients with these characteristics, evaluation of body volume status and renal function is required before starting treatment with this drug. After starting treatment, monitor for symptoms and signs of hypotension and renal function.
Dapagliflozin: The effectiveness of dapagliflozin for glycemic control depends on kidney function. Effectiveness is reduced in patients with moderate renal impairment, and administration of this drug solely for the purpose of glycemic control is not recommended in patients with type 2 diabetes with an eGFR of less than 45 mL/min/1.73m2. In patients with moderate renal impairment (eGFR less than 60 mL/min/1.73 m2), subjects treated with dapagliflozin had a higher rate of adverse reactions of elevated creatinine, phosphorus, and parathyroid hormone (PTH) and hypotension compared to subjects treated with placebo.
Metformin hydrochloride: Metformin is excreted by the kidneys, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal dysfunction. Therefore, patients with serum creatinine levels above the upper limit of normal for their age should not take this drug.
Monitoring renal function is recommended as follows:
- Before starting this medication and at least annually thereafter.
- Before and regularly after taking concomitant medications that may decrease renal function.
- If progressing to moderate renal impairment, more than 2-4 times per year. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73 m2, treatment with this drug should be discontinued.
In elderly people, renal function decline is frequent and asymptomatic. Because aging is associated with decreased renal function in elderly people, caution must be taken to set the minimum dose to achieve adequate blood sugar control. Especially in elderly patients, renal function should be monitored regularly and this drug is generally not set at the maximum dose of metformin. If you have a condition that may impair renal function (e.g., starting antihypertensive or diuretic treatment, or starting nonsteroidal anti-inflammatory drug (NSAID) treatment), special precautions are needed.
2) Use in patients at risk of volume loss and/or hypotension:
Due to the mechanism of action of dapagliflozin, an increase in urination leading to a slight decrease in blood pressure was observed in clinical studies. This may be more noticeable in patients with very high blood sugar levels.
Caution should be exercised in patients for whom drug-induced reduction in blood pressure may be at risk, such as patients diagnosed with cardiovascular disease, patients receiving antihypertensive treatment with a history of hypotension, or elderly patients.
If there are comorbidities that may cause volume loss (e.g., gastrointestinal diseases), close monitoring of fluid volume status (e.g., physical examination, blood pressure measurement, and laboratory tests including hematocrit and electrolyte tests) is recommended. For patients experiencing volume loss, temporary discontinuation of this drug is recommended until volume loss is restored.
3) Insulin secretagogues such as insulin and sulfonylureas can cause hypoglycemia. Therefore, to reduce the risk of hypoglycemia when coadministered with this drug, the dose of insulin or insulin secretagogue may need to be reduced.

4. Adverse reactions
Dapagliflozin and metformin hydrochloride
Safety results from a predefined patient population pooled from 8 placebo-controlled trials of dapagliflozin administered with immediate-release or extended-release metformin were similar to results from a pooled, predefined analysis of 13 placebo-controlled trials of dapagliprozin (see Summary of Dapagliflozin Safety Profile). In these eight clinical trials, 983 subjects received dapagliflozin 10 mg and metformin, and 1,185 subjects received placebo and metformin.
Dapagliflozin
1) Summary of safety profile
In clinical studies of patients with type 2 diabetes, more than 15,000 patients received dapagliflozin.
Safety and tolerability were assessed through a predefined pooled analysis of 13 short-term (up to 24 weeks) placebo-controlled trials involving 2,360 patients administered 10 mg of dapagliflozin and 2,295 patients administered placebo.
In a clinical trial to evaluate the cardiovascular effects of dapagliflozin (see section 13. Information for experts, 2) Clinical trial information), 8,574 people were administered dapagliflozin 10 mg and 8,569 people were administered placebo, and the average exposure period was 48 months. There were a total of 30,623 patient-years of dapagliflozin exposure. The most commonly reported adverse reactions throughout clinical studies were genital infections.

2) List of adverse reactions
The following adverse reactions were observed in placebo-controlled clinical trials. There were no dose-related adverse reactions. The adverse reactions listed below are classified according to frequency and organ system (SOC). Frequency of presentation was defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), and unknown (cannot be assessed from available data). none).
* Table: refer to manual

3) Description of specific adverse reactions
① Vulvovaginitis, balanitis and related genital infections
Pooled safety data from 13 clinical trials showed that vulvovaginitis, balanitis, and related genital infections were reported in 5.5% and 0.6% of subjects receiving dapagliflozin 10 mg and placebo, respectively. Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women (8.4% and 1.2% in the dapagliflozin and placebo groups, respectively), and subjects with a prior medical history were more likely to have recurrent infections.
In clinical trials evaluating the cardiovascular effects of dapagliflozin, the number of serious adverse events of genital infection was very small and evenly distributed (2 patients each in the dapagliflozin and placebo groups).
② Low blood sugar
The frequency of hypoglycemia depended on the type of baseline therapy used in each trial.
In additional combination studies of dapagliflozin alone, metformin, or sitagliptin (metformin alone or in combination), the frequency of mild hypoglycemic episodes was similar (<5%) between treatment groups, including placebo, up to 102 weeks of treatment. A comprehensive analysis of safety information from 1,169 patients evaluating the combination of dapagliflozin and saxagliptin under metformin baseline therapy showed a low overall incidence of hypoglycemia (≤ 1.8% in all groups) at 24 weeks. In all trials, major hypoglycemic events were uncommon and equivalent between dapagliflozin and placebo groups. The incidence of hypoglycemia was higher in studies with the addition of sulfonylurea and in studies with the addition of insulin.
In the glimepiride add-on study, mild hypoglycemic episodes were reported more frequently at weeks 24 and 48 in the glimepiride 10 mg and glimepiride combination groups (6.0% and 7.9%, respectively) compared to the placebo and glimepiride combination treatment groups (2.1% and 2.1%, respectively).
In the insulin add-on combination study, major hypoglycemic episodes were reported in 0.5% and 1.0% of patients at weeks 24 and 104, respectively, in patients administered dapagliflozin 10 mg in combination with insulin, and 0.5% were reported at weeks 24 and 104 in patients administered placebo in combination with insulin. Minor hypoglycemic episodes were reported in patients administered dapagliflozin 10 mg in combination with insulin. It was reported in 40.3% and 53.1% at weeks 24 and 104, respectively, and in patients receiving placebo with additional insulin, it was reported in 34.0% and 41.6%.
In an add-on therapy trial of metformin and sulfonylureas, no major episodes of hypoglycemia were reported by week 24. Mild hypoglycemic episodes were reported in 12.8% of subjects receiving dapagliflozin 10 mg plus metformin and sulfonylurea and in 3.7% of subjects receiving placebo plus metformin and sulfonylurea.
A clinical trial evaluating the cardiovascular effects of dapagliflozin showed that dapagliflozin therapy did not increase the risk of major hypoglycemic events compared to placebo. Major hypoglycemic events were reported in 58 patients (0.7%) in the dapagliflozin group and in 83 patients (1.0%) in the placebo group.
③ Reduction in body fluid volume
According to pooled safety data from 13 clinical trials, drug reactions suggestive of volume loss (including dehydration, hypovolemia, or hypotension) were reported in 1.1% and 0.7% of subjects receiving dapagliflozin 10 mg and placebo, respectively; Serious reactions, occurring in less than 0.2% of subjects, were evenly distributed between the dapagliflozin 10 mg and placebo groups.
In a clinical trial evaluating the cardiovascular effects of dapagliflozin, the number of patients with adverse events suggesting a decrease in body fluid volume was evenly distributed among treatment groups: 213 (2.5%) in the dapagliflozin group and 207 (2.4%) in the placebo group. Serious adverse events were reported in 81 patients (0.9%) in the dapagliflozin group and 70 patients (0.8%) in the placebo group. Adverse events were generally evenly distributed between treatment groups across subgroups, including age, use of diuretics, blood pressure, and use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. In the patient population with a baseline estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m2, 19 serious adverse events suggesting volume loss were reported in the dapagliflozin group and 13 cases in the placebo group.
④ Diabetic ketoacidosis
In a clinical trial evaluating the cardiovascular effects of dapagliflozin (median exposure period to dapagliflozin 48 months), 27 cases of diabetic ketoacidosis were reported in the patient group administered dapagliflozin 10 mg and 12 in the placebo group. Occurrence points were evenly distributed throughout the study period. Of the 27 patients in the dapagliflozin group who developed diabetic ketoacidosis, 22 were taking insulin at the time the case occurred. Factors causing diabetic ketoacidosis appeared as expected in the type 2 diabetes patient population (see ‘5. General precautions, 7) Ketoacidosis’).
⑤ Urinary tract infection
Pooled safety data from 13 clinical trials showed that urinary tract infections were reported more frequently in the dapagliflozin 10 mg group compared to the placebo group (4.7% vs 3.5%, respectively). Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women, and subjects with a previous medical history were more likely to develop recurrent infections.
In a clinical trial evaluating the cardiovascular effects of dapagliflozin, 79 cases (0.9%) of serious adverse events of urinary tract infection were reported in the dapagliflozin 10 mg group, which was less frequent than the 109 cases (1.3%) in the placebo group.
⑥ Increased creatinine
Adverse reactions associated with increased creatinine were classified as decreased renal creatinine clearance, renal impairment, increased blood creatinine, and decreased glomerular filtration rate. These adverse reactions were reported in 3.2% and 1.8% of subjects receiving dapagliflozin 10 mg and placebo, respectively. In normal subjects or patients with mild renal insufficiency (eGFR ≥ 60 mL/min/1.73 m2), these adverse reactions were reported in 1.3% and 0.8% of patients receiving dapagliflozin 10 mg and placebo, respectively. These adverse events were more reported in patients with eGFR ≥ 30 and < 60 mL/min/1.73m2. (18.5% and 9.3% with dapagliflozin 10 mg and placebo, respectively).
In the subsequent evaluation of patients with kidney-related adverse events, changes in serum creatinine of ≤ 0.5 mg/dL from baseline were observed in most patients. Increased creatinine usually occurs transiently during treatment or resolves after treatment is discontinued.
In a clinical trial (evaluating the cardiovascular effects of dapagliflozin) including elderly patients and patients with renal impairment (eGFR less than 60 mL/min/1.73m2), eGFR decreased over time in both the dapagliflozin and placebo groups. After 1 year, the average eGFR was slightly lower in the dapagliflozin group, and after 4 years, the average eGFR in the dapagliflozin group was slightly higher than the placebo group.

4) Post-marketing surveillance
The following are additional adverse drug reactions confirmed after the marketing of dapagliflozin. This adverse drug reaction was reported voluntarily from an uncharacteristic large population, so it is not possible to reliably predict its incidence.
- Ketoacidosis
- Urosepsis and pyelonephritis
- Acute kidney injury and renal dysfunction
- Rash: Rash includes the following representative terms in order of frequency in clinical studies: rash, generalized rash, pruritic rash, macular rash, maculopapular rash, pustular rash, bullous rash, and erythematous rash. In active-controlled and placebo-controlled clinical studies (5,936 people in the dapagliflozin group, 3,403 people in all control groups), the frequency of rash was similar in the dapagliflozin group (1.4%) and all control groups (1.4%) and was ‘common.’
metformin hydrochloride
In placebo-controlled monotherapy trials of extended-release metformin, diarrhea and nausea/vomiting were reported in >5% of metformin-treated patients and more commonly in placebo-controlled patients (diarrhea 9.6% vs 2.6%, nausea/vomiting 6.5% vs 1.5%). Diarrhea caused discontinuation of the test drug in 0.6% of patients receiving sustained-release metformin.
Vitamin B12 reduction/deficiency has been commonly reported.

5) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 623 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 14.29% (89/623 people, 113 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
* Table: refer to manual

5. General precautions
1) Lactic acidosis
Metformin Hydrochloride: Lactic acidosis is a very rare but serious metabolic complication that can occur due to accumulation of metformin during treatment with this drug; It is fatal in approximately 50% of cases. Lactic acidosis occurs frequently in acute renal dysfunction, cardiopulmonary disease, and sepsis. Lactic acidosis may also occur when there is significant tissue hypoperfusion and hypoxemia, which is associated with several pathophysiological conditions, including diabetes. Lactic acidosis is characterized by increased blood lactate levels (>5 mmol/L), decreased blood pH, electrolyte imbalance with increased anion gap, and increased lactate/fibrate ratio. When metformin contributes to the cause of lactic acidosis, plasma levels of metformin are typically greater than 5 ug/mL.
The reported rate of lactic acidosis in patients receiving metformin hydrochloride is very low (approximately 0.03 cases/1000 person-years, 0.015 fatal cases/1000 person-years). In over 20,000 person-years exposed to metformin in clinical trials, there were no reports of lactic acidosis. Reported cases have primarily occurred in diabetic patients with significant renal impairment, including intrinsic renal disease and renal hypoperfusion, often with multiple coexisting medical/surgical problems and with multiple concomitant medications. The risk of lactic acidosis is increased in patients with congestive heart failure requiring medical treatment, especially those with unstable or acute congestive heart failure and at risk for hypoperfusion and hypoxemia. The risk of lactic acidosis increases with the degree of renal impairment and the patient's age.
Additionally, metformin should be discontinued immediately if there are any conditions associated with hypoxemia, dehydration, or sepsis. Because hepatic dysfunction can significantly limit the ability to eliminate lactic acid, metformin should generally be avoided in patients with clinical or laboratory evidence of liver disease. Because alcohol enhances the effect of metformin on lactic acid metabolism, caution should be exercised against excessive alcohol consumption when taking metformin.
The presentation of lactic acidosis is often difficult to detect and is accompanied by only non-specific symptoms such as malaise, muscle pain, dyspnea, asthenia, and non-specific abdominal pain. If acidosis becomes more severe, hypothermia, hypotension, and resistant bradyarrhythmia may occur. Patients and doctors should be aware of the possible significance of these symptoms, and patients should notify their doctors immediately if they occur. Metformin should be discontinued until the situation becomes clear. Serum electrolytes, ketones, blood glucose and, if necessary, blood pH (<7.35), lactic acid levels and even blood metformin levels may be useful. Once patients have stabilized on a certain dose level of metformin, the gastrointestinal symptoms common at the start of treatment are rarely drug-related. Gastrointestinal symptoms that occur later may be due to lactic acidosis or other serious diseases.
In patients taking metformin, fasting venous plasma lactate levels above the upper limit of normal but less than 5 mmol/L do not necessarily indicate lactic acidosis but may be explained by other mechanisms, such as poorly controlled diabetes or obesity, vigorous physical activity, or technical problems in sample processing.
Lactic acidosis should be suspected in all diabetic patients with metabolic acidosis without evidence of ketoacidosis (ketonuria, ketonemia). Lactic acidosis is a medical emergency and must be treated in hospital. In patients with lactic acidosis taking metformin, the drug should be discontinued immediately and general supportive care should be initiated immediately. Because metformin hydrochloride is dialyzable (with a clearance rate of up to 170 mL/min under good hemodynamic conditions), rapid hemodialysis is recommended to correct acidosis and remove accumulated metformin. These measures can often quickly eliminate symptoms and lead to recovery.

2) Changes in clinical status of patients with previously controlled type 2 diabetes
Metformin hydrochloride: In patients with type 2 diabetes who were previously well controlled with this drug, if laboratory abnormalities or clinical abnormalities (especially symptoms that are vague and difficult to characterize) occur, evaluation should be promptly conducted to find evidence of ketoacidosis or lactic acidosis. This assessment should include serum electrolytes and ketones, blood glucose, and, as indicated, blood pH, lactic acid, fibric acid, and metformin concentrations. If ketoacidosis or lactic acidosis occurs, this drug should be discontinued immediately and other appropriate corrective treatment should be initiated.

3) Impaired liver function
Clinical trial experience in patients with hepatic impairment is limited. Exposure to this drug is increased in patients with severe hepatic impairment.
Metformin hydrochloride: Impaired liver function has been associated with some cases of lactic acidosis in patients receiving metformin, so this drug is not administered to patients with hepatic impairment.

4) Administration of iodine contrast agent
Metformin hydrochloride: Intravascular administration of iodinated contrast agents can cause rapid changes in renal function and are associated with lactic acidosis in patients receiving metformin. Therefore, the administration of this drug should be temporarily stopped at or before the procedure, withheld until 48 hours after the procedure, and then restarted after renal function is reevaluated and confirmed to be normal.

5) Hypoxia state
Metformin hydrochloride: Cardiovascular collapse (shock) of any cause, acute congestive heart failure, acute myocardial infarction, and other conditions presenting with hypoxia are also associated with lactic acidosis and may also cause systemic azotemia. If this condition occurs in a patient taking this drug, discontinue treatment immediately.

6) Surgery
Metformin hydrochloride: Because this medication contains metformin hydrochloride, it should be discontinued 48 hours before surgical procedures with general, spinal, or epidural anesthetics. Treatment with this drug should be restarted after at least 48 hours have passed and renal function is confirmed to be normal.

7) Ketoacidosis
Dapagliflozin: Reports of serious, life-threatening ketoacidosis requiring prompt hospitalization have been identified in patients with type 1 and type 2 diabetes mellitus treated with SGLT2 inhibitors, including dapagliflozin. Fatal cases of ketoacidosis have been reported in patients treated with dapagliflozin.
Ketoacidosis associated with this medicine may occur even when blood glucose is below 250 mg/dL. Patients treated with this medicine who show signs and symptoms consistent with severe metabolic acidosis should therefore be evaluated for ketoacidosis regardless of their blood glucose level. If ketoacidosis is suspected, discontinue this medicine, assess the patient’s condition and initiate treatment promptly. Glucosuria and ketoacidosis may persist longer than generally expected, and urinary glucose excretion may continue for 3 days after discontinuation. However, postmarketing reports describe glucosuria and ketoacidosis persisting for more than 6 days and up to 2 weeks after stopping an SGLT2 inhibitor.
Treatment of ketoacidosis may require insulin, fluid, and carbohydrate replacement. Symptoms and signs of ketoacidosis are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, decreased appetite, abdominal pain, malaise, and difficulty breathing. Some reports have identified factors predisposing to ketoacidosis to include reduced insulin dose, acute febrile illness, restricted calorie intake due to illness or surgery, ketogenic diet, pancreatic disorders causing insulin deficiency (e.g., type 1 and 2 diabetes, pancreatitis, or history of pancreatic surgery), and alcohol abuse.
Before starting treatment with this medication, factors that may predispose to ketoacidosis, including decreased insulin secretion, calorie restriction, and alcohol abuse, should be considered. Monitor patients treated with this drug for the development of ketoacidosis, and consider temporarily discontinuing this drug if clinical situations predisposing to ketoacidosis (e.g., prolonged fasting due to acute illness or surgery) occur.

8) Urosepsis and pyelonephritis
Dapagliflozin: Serious urinary tract infections, including urosepsis and pyelonephritis, have been reported post-marketing in patients using dapagliflozin and other SGLT2 inhibitors. SGLT2 inhibitor therapy increases the risk of urinary tract infections. If necessary, evaluate the patient's signs and symptoms of urinary tract infection and promptly treat them.

9) Reproductive infections (including fungi)
Dapagliflozin: Dapagliflozin increases the risk of genital infections (including fungal). Patients with a history of genital infections (including fungal) are more likely to develop genital infections (including fungal). Observe and treat appropriately.

10) Vitamin B12 concentration
Metformin can decrease vitamin B12 levels. The risk of low vitamin B12 levels increases in patients with higher metformin doses, longer treatment duration, and/or with risk factors known to cause vitamin B12 deficiency. If vitamin B12 deficiency is suspected (such as anemia or neuropathy), serum vitamin B12 levels should be monitored. Regular vitamin B12 monitoring may be necessary for patients with risk factors for vitamin B12 deficiency. Metformin therapy should be continued unless tolerated and contraindicated, and appropriate corrective treatment for vitamin B12 deficiency should be provided according to current clinical guidelines.

11) Alcohol consumption
Metformin Hydrochloride: Alcohol is known to enhance the effects of metformin on lactic acid metabolism. Therefore, patients should avoid acute or chronic excessive intake of alcohol while taking this medicine.

12) Failure to control blood sugar levels
Metformin Hydrochloride: Patients stabilized on certain diabetes treatments may temporarily lose blood sugar control when exposed to stress such as fever, cramps, infection, or surgery. At these times, this drug may be discontinued and temporary insulin administration may be required. This drug may be resumed after the acute crisis has resolved.

13) Use of drugs that cause hypoglycemia
Insulin secretagogues such as insulin and sulfonylureas cause hypoglycemia. Therefore, when used in combination with this drug, the dose of insulin or insulin secretagogue may need to be reduced to reduce the risk of hypoglycemia.
Hypoglycemia does not occur in patients taking metformin alone under normal use circumstances, but can occur when caloric intake is insufficient, when caloric supplementation is not made after strenuous exercise, or during concurrent use with other hypoglycemic agents (such as sulfonylureas and insulin) or alcohol. Elderly, debilitated, or malnourished patients, as well as patients with adrenal or pituitary insufficiency or alcoholism, are prone to hypoglycemia. Hypoglycemia may be difficult to recognize in the elderly and patients taking β-adrenergic blocking drugs.

14) SGLT2 inhibitors such as dapagliflozin may theoretically worsen the condition of patients with underlying bladder diseases that may affect urinary function by increasing urine output. Therefore, caution is required when prescribing SGLT2 inhibitors such as dapagliflozin to these patients.

15) Combination therapy
Dapagliflozin has not been studied in combination with GLP-1 analogues.

16) Urine laboratory evaluation
Patients receiving this drug will test positive for urinary glucose due to dapagliflozin's mechanism of action.

17) Lower limb amputation
In long-term clinical studies of other SGLT2 inhibitors, an increase in lower extremity amputations (mainly toes) was observed. It has not been confirmed whether this case applies to the entire series. As with all patients with diabetes, it is important to counsel patients about routine preventive foot care.

18) Weight loss
In a 24-week, placebo-controlled study of dapagliflozin monotherapy in patients with inadequately controlled type 2 diabetes, the change in body weight from baseline was −3.16 kg with dapagliflozin and −2.19 kg with placebo, indicating greater weight loss with dapagliflozin.

19) Perineal gangrene (Fournier’s gangrene)
In post-marketing studies in diabetic patients taking SGLT2 inhibitors, rare but serious cases of life-threatening perineal gangrene requiring prompt surgical intervention have been reported. Perineal gangrene has been reported in both men and women, resulting in hospitalization, multiple surgeries, and death.
If a patient receiving this drug develops pain, maceration, erythema, or swelling around the genitals or perineum along with fever and discomfort, perineal gangrene should be checked. If perineal gangrene is suspected, broad-spectrum antibiotic treatment should be started immediately and surgical resection should be performed if necessary. This drug should be discontinued, blood sugar levels should be closely monitored, and appropriate alternative treatment should be implemented to control blood sugar.

6. Interaction
Dapagliflozin
1) Pharmacodynamic interaction
① Diuretics: Dapagliflozin may increase the diuretic effect of thiazides and loop diuretics and may increase the risk of dehydration and hypotension.
② Insulin and insulin secretion stimulants: Insulin secretion stimulants such as insulin and sulfonylureas can cause hypoglycemia. Therefore, to reduce the risk of hypoglycemia when administered in combination with dapagliflozin, the dose of insulin or insulin secretagogue may need to be reduced.

2) Pharmacokinetic interactions
① The metabolism of dapagliflozin is mainly accomplished through glucuronide conjugation mediated by UDP-glucuronidase 1A9 (UGT1A9).
② In laboratory (in-vitro) studies, dapagliflozin did not inhibit cytochrome P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, or induce CYP1A2, CYP2B6, or CYP3A4. Therefore, dapagliflozin is not expected to alter the metabolic excretion of drugs metabolized by these enzymes when coadministered with these drugs.

3) Effect of other medicines on dapagliflozin
① As a result of an interaction study conducted on healthy subjects mainly using a single-dose design, the pharmacokinetics of dapagliflozin were not changed by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
② After co-administering dapagliflozin with rifampicin (an inducer of various active transporters and drug-metabolizing enzymes), a 22% decrease in dapagliflozin systemic exposure (AUC) was observed, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended. Clinically relevant effects are not expected with other inducers (e.g., carbamazepine, phenytoin, phenobarbital).
③ After co-administering dapagliflozin with mefenamic acid (an inhibitor of UGT1A9), systemic exposure to dapagliflozin increased by 55%, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended.

4) Effect of dapagliflozin on other medicines
Dapagliflozin may increase renal excretion of lithium and decrease blood lithium concentrations. Serum lithium concentrations should be monitored more frequently upon initiation of dapagliflozin and after dose changes. Refer the patient to the doctor who prescribed lithium to monitor the serum lithium concentration.
In interaction studies conducted in healthy subjects, primarily using a single-dose design, dapagliflozin had an anticoagulant effect on the pharmacokinetics of metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (a P-gp substrate), or warfarin (S-warfarin, a CYP2C9 substrate), or the anticoagulant activity of warfarin as assessed by INR. didn't change A single co-administration of dapagliflozin 20 mg and simvastatin (CYP3A4 substrate) resulted in a 19% increase in simvastatin AUC and a 31% increase in simvastatin acid AUC. Elevated simvastatin and simvastatin acid exposure are not considered clinically relevant.

5) Other interactions
The effects of smoking, diet, herbal medicines and alcohol on the pharmacokinetics of dapagliflozin have not been studied.

6) Pediatric
Interaction studies were conducted only in adults.

metformin hydrochloride
1) Drugs that may affect this drug, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, or are excreted through renal tubular secretion: Metformin is a substrate of the organic cation transporter (OCT) OCT1 and OCT2.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Since OCT inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be carefully monitored when administered in combination with metformin. Must observe.

2) Glibenclamide: In a single-dose study on patients with type 2 diabetes, co-administration of metformin hydrochloride and glibenclamide did not change the pharmacokinetics or pharmacodynamic properties of metformin hydrochloride. A decrease in the AUC and Cmax of glibenclamide was observed, but the deviation was large. The lack of correlation between blood concentrations and pharmacokinetic effects of single-dose metformin hydrochloride in this study indicates that the clinical significance of this interaction is unclear.

3) Furosemide: A study on the drug interaction of metformin hydrochloride and furosemide administered as a single dose in healthy people showed that the pharmacokinetic values of each substance were affected by co-administration. Furosemide increases the plasma concentration of metformin hydrochloride without significant changes in the renal clearance of metformin hydrochloride, and increases blood Cmax by 22% and blood AUC by 15%. When administered together with metformin hydrochloride, the Cmax and AUC of furosemide are reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide is reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction when metformin hydrochloride and furosemide are co-administered chronically.

4) Nifedipine: A study on the drug interaction between metformin hydrochloride and nifedipine in a single dose in normal healthy volunteers showed that co-administration with nifedipine increases the Cmax and AUC of metformin hydrochloride in plasma by 20% and 9%, respectively, and increases urinary excretion. Tmax and half-life are not affected. Nifedipine promotes the absorption of metformin hydrochloride. Metformin hydrochloride does not significantly affect nifedipine.

5) Use with other drugs: Some drugs cause hyperglycemia and may lead to failure in blood sugar control. These drugs include thiazines and other diuretics, corticosteroids, phenothiazines, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel antagonists, and isoniazid. When such drugs are administered to patients receiving metformin, the patient's glycemic control should be carefully monitored. When such drugs are discontinued in patients receiving metformin, the patient should be carefully monitored for hypoglycemia. In single-dose co-administration studies in healthy volunteers, the pharmacokinetic properties of metformin hydrochloride and propranolol and metformin hydrochloride and ibuprofen were not affected by each other.

6) Since the binding of metformin hydrochloride to plasma proteins is negligible, there is little interaction with drugs that bind to proteins in large quantities, such as salicylic acid, sulfonamides, chloramphenicol, and probenecid, compared to sulfonylureas that bind extensively to plasma proteins.
Interference in 1,5-Anhydroglucitol Testing
The 1,5-anhydroglucitol test is not recommended as a blood sugar control monitoring test in patients taking SGLT2 inhibitors because the reliability of the measurement results is low. Different methods are used to monitor blood sugar control.

7. Administration to pregnant and lactating women
1) Administration to pregnant women: There are no suitable, well-controlled clinical trials or tests for each ingredient targeting pregnant women. This drug is not used in pregnant women. Once pregnancy is confirmed, treatment with this drug should be discontinued.
A study on dapagliflozin in rats showed toxicity to kidney development during the period equivalent to the second and third trimesters of human pregnancy. Therefore, dapagliflozin should not be used during the second and third trimesters of pregnancy.
The effects of dapagliflozin on human fertility have not been studied. In male and female rats, dapagliflozin showed no effects on fertility at any of the doses studied.
2) Administration to lactating women: This drug should not be used while breastfeeding. Studies on lactating animals have not been conducted with the combined components of this drug. In studies conducted with each component, both dapagliflozin and metformin are excreted in the milk of lactating rats. Animal pharmacodynamic data for dapagliflozin have also shown pharmacologically mediated effects in lactating offspring. Risk to neonates/infants cannot be excluded.
It is not known whether dapagliflozin or metformin are excreted in human milk.

8. Administration to children
The safety and effectiveness of this drug in pediatric patients have not been established.

9. Administration to elderly people
1) Dapagliflozin
Elderly patients are more likely to have renal impairment or be taking antihypertensive drugs that can cause changes in renal function, such as angiotensin-converting enzyme inhibitors (ACE®I) and type 1 angiotensin II receptor inhibitors (ARBs). The same recommendations regarding renal function apply to elderly patients as to all patients.
Elderly patients may be at higher risk for volume loss and are more likely to be taking diuretics.
From a pharmacokinetic perspective, there are insufficient data to make conclusions regarding blood drug exposure in patients over 70 years of age.
2) Metformin hydrochloride
Because patients over 80 years of age are prone to developing lactic acidosis, metformin should not be administered to patients over 80 years of age unless it is confirmed that there is no decrease in renal function as a result of creatinine clearance measurement. Initial and maintenance doses of metformin should be cautious in elderly patients due to the potential for decreased renal function. All dosage adjustments should be based on careful evaluation of renal function (3. Administer with caution to the following patients, see section 1) Acute kidney injury and renal dysfunction).

10. Treatment in case of overdose
1) Dapagliflozin: Orally administered dapagliflozin did not show any toxicity in a single oral dose of up to 500 mg (50 times the maximum recommended dose (MRHD) for humans) in healthy subjects. These subjects had detectable urinary glucose throughout the treatment period (more than 5 days for the 500 mg dose), no dehydration, hypotension, or electrolyte imbalances were reported, and there were no clinically significant effects on the QTc interval. The incidence of hypoglycemia was similar to placebo. In clinical trials in which healthy subjects and patients with type 2 diabetes were administered doses up to 100 mg (10 times the maximum recommended human dose) once daily for 2 weeks, the incidence of hypoglycemia was slightly higher than in the placebo group and was not dose-related. Rates of adverse events, including dehydration or hypotension, were similar to the placebo group, and there were no clinically significant dose-related changes in laboratory parameters, including serum electrolytes and biomarkers of renal function.
If overdose occurs, appropriate symptomatic treatment should be administered according to the patient's clinical condition. Elimination of dapagliflozin by dialysis has not been studied.

2) Metformin hydrochloride: Overdosage of metformin hydrochloride has been reported, including cases of ingestion of amounts exceeding 50g.
Lactic acidosis has been reported in approximately 32% of metformin overdoses. Metformin is dialyzable with a clearance rate of up to 170 mL/min under good hemodynamic conditions. Therefore, dialysis may be useful in removing accumulated drug in patients suspected of metformin overdose.

11. Precautions for application
Studies have not been done to determine whether this drug or dapagliflozin affects the ability to drive or use machines. Dapagliflozin or metformin will have little effect on patients' ability to drive or use machines. Dizziness has been reported in clinical trials of dapagliflozin, so this should be taken into consideration.

12. Precautions for storage and handling
Keep out of reach of children.
Removing medicines from their original container and storing them in another container may cause accidents due to misuse of medicines or cause a decrease in the quality of medicines, so store them in their original containers.

13. Information for experts
1) Dapagliflozin mechanism of action: Dapagliflozin is a very potent (Ki: 0.55 nM), selective and reversible inhibitor of sodium-glucose-cotransporter 2 (SGLT2).
SGLT2 is selectively expressed in the kidney and has no detectable expression in over 70 other tissues, including liver, skeletal muscle, adipose tissue, breast, bladder, and brain. SGLT2 is the main transporter involved in the process of glucose reabsorption from glomerular filtrate into systemic circulation. In type 2 diabetes, reabsorption of filtered glucose continues despite the presence of hyperglycemia. Dapagliflozin reduces glucose reabsorption in the kidneys, resulting in urinary glucose excretion, thereby improving fasting and postprandial plasma glucose levels. This glucuretic effect observed from the first administration of the drug is maintained throughout the 24-hour dosing interval and persists throughout the treatment period. The amount of glucose eliminated by the kidneys through this mechanism is dependent on blood glucose concentration and GFR. Dapagliflozin does not impair normal endogenous glucose production in response to hypoglycemia. The action of dapagliflozin is unrelated to insulin secretion and action. Urinary glucose excretion (glucuresis) induced by dapagliflozin leads to calorie loss and weight loss. Inhibition of co-transport of glucose and sodium by dapagliflozin results in mild diuresis and temporary increase in sodium excretion.
Dapagliflozin does not inhibit other glucose transporters important for glucose transport to peripheral tissues and is >1400-fold selective for SGLT2 compared to SGLT1, the major transporter responsible for glucose absorption in the digestive tract.
2) Clinical trial information
Initial combination therapy of dapagliflozin and metformin
Two 24-week active-controlled studies were conducted to evaluate the efficacy and safety of initial combined administration of dapagliflozin and extended-release metformin in patients with type 2 diabetes who had no prior drug treatment. When dapagliflozin 10 mg and metformin were administered together, HbA1c was significantly reduced compared to each administration alone (see Table 2).
* Table: refer to manual

An active-controlled trial comparing dapagliflozin plus the addition of a sulfonylurea (glipizide) in patients with inadequate glycemic control on metformin.
A 52-week active control non-inferiority study (52 weeks and 104 weeks extension) was conducted to compare and evaluate the additional use of dapagliflozin and sulfonylurea (glipizide) to metformin in patients with type 2 diabetes who had insufficient glycemic control with metformin (HbA1c greater than 6.5% but less than 10%). As a result, dapagliflozin demonstrated non-inferiority by showing a similar reduction in HbA1c compared to baseline at 52 weeks as glipizide (see Table 3). At week 104, the reduction in HbA1c compared to baseline was -0.32% for dapagliflozin and -0.14% for glipizide. The incidence of one or more hypoglycemic events was significantly lower in the dapagliflozin group (3.5% and 4.3% for 52 and 104 weeks, respectively) than in the glipizide group (40.8% and 47.0% for 52 and 104 weeks, respectively).
* Table: refer to manual

Additional combination therapy with other hypoglycemic agents
When dapagliflozin was added to metformin (see Table 4), insulin and metformin (see Table 5), sitagliptin and metformin (see Table 6), metformin and sulfonylurea (see Table 7), and metformin and saxagliptin (see Table 8), there was a statistically significant decrease in HbA1c compared to placebo at 24 weeks (p < 0.0001).
In a trial in which dapagliflozin was added to metformin, the HbA1c reduction effect was maintained even at 102 weeks.
* Table: refer to manual

Patients with moderate renal impairment stage 3A (eGFR 45-60 mL/min/1.73m2)
Dapagliflozin
In a study limited to diabetic patients with an eGFR of 45 to 60 mL/min/1.73m2, the effectiveness of additional administration of dapagliflozin was evaluated in patients whose glycemic control was inadequate with existing therapy. Dapagliflozin showed a decrease in HbA1c as shown in Table 9 compared to placebo.
* Table: refer to manual

fasting blood sugar
When dapagliflozin 10 mg was administered with metformin alone or in combination with metformin and sitagliptin or sulfonylurea or saxagliptin or insulin, it statistically significantly reduced fasting blood sugar compared to placebo. This effect was maintained throughout the trial, which extended from the first week of administration to 104 weeks.
In a study limited to diabetic patients with dapagliflozin eGFR 45-60 mL/min/1.73 m2, the fasting blood sugar level at 24 weeks of administration was -0.27 mmol/L (-4.87 mg/dL) with placebo and -1.19 mmol/L (-21.46 mg/dL) with dapagliflozin.
postprandial blood sugar
When dapagliflozin 10 mg was added to the combination of sitagliptin and metformin, a decrease in 2-hour postprandial blood sugar levels was observed at 24 weeks and was maintained until 48 weeks.
Effects of dapagliflozin on the cardiovascular system and kidneys
The DECLARE study was a multinational, multicenter, randomized, double-blind, placebo-controlled clinical trial conducted to determine the effects of dapagliflozin compared to placebo on the cardiovascular system and kidneys when added to existing treatment regimens. In addition to type 2 diabetes, all patients had at least two cardiovascular risk factors (men over 55 years of age or women over 60 years of age, at least one of dyslipidemia, hypertension, or current smoking) or had cardiovascular disease.
Among the 17,160 patients, 6,974 (40.6%) had cardiovascular disease and 10,186 (59.4%) did not have cardiovascular disease. 8,582 people were randomly assigned to receive dapagliflozin 10 mg and 8,578 were randomly assigned to placebo. The median follow-up period was 4.2 years.
The average age of the group participating in the study was 63.9 years, of which 37.4% were women. The average duration of diabetes for all patients was 11.9 years, and 22.4% had diabetes for less than 5 years. The average HbA1c was 8.3% and the average body mass index was 32.1 kg/m2.
At baseline, 10.0% of patients had a history of heart failure. The average eGFR was 85.2 mL/min/1.73m2. 7.4% of patients had an eGFR less than 60 mL/min/1.73m2, and 30.3% of patients had microalbuminuria [urinary albumin-to-creatinine ratio (UACR) of 30 mg/g or more - 300 mg/g or less] or macroalbuminuria (UACR of 300 mg/g). There was an excess).
Most patients (98%) were receiving at least one medicine for diabetes at baseline: 82% were taking metformin, 41% insulin and 43% a sulfonylurea.
Approximately 81.3% of patients received an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 75.0% a statin, 61.1% an antiplatelet agent, 55.5% aspirin, 52.6% a beta-blocker, 34.9% a calcium channel blocker, 22.0% a thiazide diuretic and 10.5% a loop diuretic.
Major cardiovascular events
Dapagliflozin 10 mg demonstrated non-inferiority to placebo for the composite endpoint of adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke (one-sided p<0.001).
Hospitalization due to heart failure or death from cardiovascular disease
Dapagliflozin 10 mg was superior to placebo for the primary composite endpoint of preventing hospitalization for heart failure or cardiovascular death (Figure 1).
In an exploratory analysis of each factor, a significant decrease in the incidence of hospitalization due to heart failure contributed to the difference in treatment effect, and there was no significant difference in cardiovascular disease mortality.
The treatment benefit of dapagliflozin compared to placebo was observed regardless of baseline cardiovascular disease and underlying heart failure, and was consistent across key subgroups including age, gender, renal function (eGFR), and region.
* Picture: refer to manual

nephropathy
Height-related endpoints were evaluated for exploratory purposes.
Dapagliflozin reduced the incidence of multiple events, including confirmed persistent eGFR decline, end-stage renal disease, and renal or cardiovascular death. Differences between treatment groups were seen in the reduction of renal events, including persistent eGFR decline, end-stage renal disease, and kidney-related death.
The hazard ratio (HR) for dapagliflozin compared with placebo for time to nephropathy event (persistent eGFR decline, end-stage renal disease, or kidney-related death) was 0.53 [95% CI 0.43, 0.66].
In patients with no history of albuminuria, dapagliflozin reduced the new onset of persistent albuminuria (UACR > 30 mg/g) compared to placebo (hazard ratio (HR) 0.79 [95% CI 0.72, 0.87]), and in patients with a history of macroalbuminuria, the reduction in macroalbuminuria was greater in the dapagliflozin group than in the placebo group (hazard ratio (HR) 1.82 [95% CI 1.51, 2.20].
3) Non-clinical safety data
Dapagliflozin
① Carcinogenicity: Dapagliflozin did not induce tumors in mice or rats at any of the doses evaluated in the 2-year carcinogenicity study. The oral doses in mice were 5, 15, and 40 mg/kg/day for males and 2, 10, and 20 mg/kg/day for females, and the oral doses for rats were 0.5, 2, and 10 mg/kg/day for both sexes. The highest dose evaluated in mice corresponded to an AUC exposure multiple of approximately 72 (males) and 105 (female) the human AUC at the maximum recommended human dose (MRHD) of 10 mg per day. The AUC exposure in rats was approximately 131 times (males) and 186 times (females) the human AUC at MRHD.
② Genotoxicity: Dapagliflozin was negative in the Ames mutagenicity test and positive in the in vitro chromosomal abnormality induction test, but this was true when the concentration was over 100 mg/mL under S9 activity conditions. In particular, dapagliflozin was negative for chromosomal abnormalities in in vivo conditions in micronucleus or DNA repair tests conducted on rats at an exposure equivalent to more than 2,100 times the human exposure in MRHD. These studies support that dapagliflozin does not present a genotoxic risk to humans, given the absence of neoplastic findings in rat and mouse carcinogenicity studies.
③ Reproductive dysfunction: In fertility and early embryo development tests on rats, 15, 75, or 300/210 mg/kg/day of dapagliflozin was administered to males (300 mg/kg/day dose was reduced to 210 mg/kg/day after 4 days), and 3, 15, or 75 mg/kg/day doses were administered to females. Dapagliflozin did not affect mating, fertility, or early embryonic development in males or females at any dose administered (fold exposure ≤1708 and 998 times the MRHD in males and females). However, at 300/210 mg/kg/day, seminal vesicle and epididymal weight decreased, sperm motility and sperm count decreased, and the number of morphologically abnormal sperm was low.
④ Teratogenicity: Direct administration to young rats during the weaning period and indirect exposure to the drug during the second half of pregnancy and lactation (the period corresponding to the second and third trimesters of pregnancy in relation to human kidney development) are associated with an increase in the severity and incidence of renal pelvis dilatation and tubular dilatation in offspring. In a toxicity study in young animals, when dapagliflozin was administered to young rats on the 21st day of life at doses of 1, 15, or 75 mg/kg/day for up to 90 days, renal pelvis dilatation and tubular dilatation were reported at all doses; Exposure to offspring at the lowest dose was more than 15 times the MRHD. These observations were associated with a dose-related increase in kidney mass and macroscopic renal hypertrophy at all doses. The renal pelvis and tubular dilatation observed in young animals were not completely reversed during a recovery period of approximately 1 month.
⑤ Early developmental disorders: In a separate study on prenatal and postnatal development, maternal rats were administered drugs (1, 15, or 75 mg/kg/day) from the 6th day of pregnancy to the 21st day after birth, and the offspring were exposed indirectly through uterus and breastfeeding. (A separate study was conducted to evaluate the effects of dapagliflozin on milk and offspring.) Increased severity or incidence of renal pelvic dilatation was again observed in adult offspring of dams receiving the dose, albeit only at a dose of 75 mg/kg/day (corresponding to maternal and offspring dapagliflozin exposures of 1415 and 137 times [human levels in MRHD], respectively). Additional developmental toxicity was limited to a dose-related reduction in offspring body weight, which was observed at doses above 15 mg/kg/day (a offspring exposure greater than 29 times the human value in MRHD). Maternal toxicity was evident only at 75 mg/kg/day and was limited to a transient decrease in body weight and food consumption at the beginning of administration. The NOAEL for developmental toxicity, 1 mg/kg/day, is approximately 19 times the [human level in MRHD] and corresponds to maternal systemic exposure.
In additional embryo-fetal development studies in rats and rabbits, dapagliflozin was administered at intervals corresponding to key periods of organogenesis in each species. No maternal or developmental toxicity was observed in rabbits at any dose administered (20, 60, or 180 mg/kg/day); 180 mg/kg/day corresponds to a systemic exposure approximately 1191 times the MRHD. In rats, dapagliflozin was not embryonic lethal or teratogenic up to a dose of 75 mg/kg/day (approximately 1441 times the MRHD). Maternal and developmental toxicity was associated at a dose of 150 mg/kg/day (approximately 2344 times [human level in MRHD]). Maternal toxicity includes mortality, abnormal clinical signs, and reduction in body weight and food consumption. Developmental toxicities include embryo-fetal mortality, increased fetal malformations and skeletal dysmorphic events, and reduced fetal weight. The malformations are macrovascular malformation, costal and central spinal fusion, and sternum and central sternal duplication. The variation was mainly reduced ossification.
⑥ Animal toxicology: Most effects observed in major repeated-dose toxicity tests on rats and dogs were judged to be accompanied by pharmacologically mediated increases in urinary glucose, and included weight loss and/or decreased body weight gain rate, increased feed consumption, and increased urine volume due to osmotic diuretics. Dapagliflozin was well tolerated when administered orally to rats at a dose of 25 mg/kg/day (more than 346 times the human exposure at MRHD) for up to 6 months and to dogs at a dose of 120 mg/kg/day (more than 3200 times the human exposure at MRHD) for up to 12 months. In addition, as a result of a single-dose test of dapagliflozin, in both rat and dog toxicity tests, dapagliflozin 3-O-glucuronide metabolites were formed at an exposure level (AUC) equivalent to or higher than the expected human dapagliflozin 3-O-glucuronide exposure after administration of dapagliflozin in MRHD. The most notable nonclinical toxicological findings in rats, increased cancellous bone and tissue mineralization (related to increased serum calcium), were observed only at high exposure multiples (>2100-fold based on human exposure at MRHD). Despite reaching an exposure multiple of more than 3200 times the human exposure at MRHD, there were no dose limitations or target organ toxicities in the 12-month dog study.
metformin hydrochloride
① Carcinogenicity: Long-term carcinogenicity tests were conducted in rats (dose period: 104 weeks) and mice (dose period: 91 weeks) up to 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are all approximately four times the maximum recommended human dose of 2000 mg based on body surface area comparison. No evidence for metformin's carcinogenicity was found in either male or female mice. Similarly, the carcinogenic potential of metformin has not been observed in male rats. However, the incidence of benign stromal uterine polyps increased in female rats administered at 900 mg/kg/day.
② Genotoxicity: There was no mutagenic potential of metformin in the following laboratory tests: Ames test (S. typhimurium), gene mutation test (mouse lymphoma cells), or chromosomal abnormality test (human lymphocytes). The in vivo mouse micronucleus test result was also negative.
③ The fertility of male and female rats was not affected by this drug when administered at a high dose of 600 mg/kg/day, or about 3 times the maximum allowable dose based on body surface area.
④ Metformin was not teratogenic when administered to rats and rabbits at doses up to 600 mg/kg/day. This represents exposures approximately 2 and 6 times the maximum recommended human dose of 2000 mg based on body surface area comparisons in rats and rabbits, respectively. Fetal concentration measurements demonstrated a partial placental barrier to metformin.

4) Pharmaceutical equivalence test information
A. Dapagliflozin
The test drug Dapamet extended-release tablets 10/1000 mg [KyungDong Pharm Co., Ltd.] and the reference drug Zigduo extended-release tablets 10/1000 mg [Korea AstraZeneca Korea Co., Ltd.] were administered orally once on an empty stomach to healthy adults in a 2 When subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
* Table: refer to manual

B. metformin
The test drug Dapamet extended-release tablets 10/1000 mg [KyungDong Pharm Co., Ltd.] and the control drug Zigduo extended-release tablets 10/1000 mg [Korea AstraZeneca Korea Co., Ltd.] were administered orally once, one tablet each, on an empty stomach and after a meal to healthy adults in a 2×2 crossover study. As a result, metformin in the blood of 32 people (fasting) and 37 people (after a meal) was measured. When comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log0.8 to log1.25, demonstrating biological equivalence.
* Table: refer to manual

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 2items

No.Product NameDetailsDate of ChangeDownload
2Dapamet SR Tab. 10/500mgIndications, Dosage and Administration, and Precautions for Use2026.11.11PDFUnification adjustment of dapagliflozin-metformin combination drug (draft).pdf
1Dapamet SR Tab. 10/500mgPrecautions for use2025.08.29PDF0298_202108077_Precautions for use (Dapamet extended-release tablet 10_500mg).pdf